Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration is a research paper published in Brain (2022). On theSindex it has a DataRank of 0. It has been cited 239 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Swedish Research Council
Grant: #2018-02532
Swedish Research Council
Grant: #2017-00915
Swedish Research Council
Grant: #2021-03244
European Research Council
Grant: #681712
European Research Council
Grant: #101053962
Swedish State Support for Clinical Research
Grant: #ALFGBG-71320
Alzheimer Drug Discovery Foundation
Grant: #201809-2016862
Alzheimer’s disease Strategic Fund and the Alzheimer’s Association
Grant: #ADSF-21-831376-C
Alzheimer’s disease Strategic Fund and the Alzheimer’s Association
Grant: #ADSF-21-831381-C
Alzheimer’s disease Strategic Fund and the Alzheimer’s Association
Grant: #ADSF-21-831377-C
Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden
Grant: #FO2019-0228
Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden
Grant: #RDAPB-201809-2016615
Neurodegenerative Disease Research
Grant: JPND2021-00694
UK Dementia Research Institute at UCL
Grant: UKDRI-1003
Swedish Alzheimer Foundation
Grant: #AF-930351
Swedish Alzheimer Foundation
Grant: #AF-939721
Swedish Alzheimer Foundation
Grant: #AF-968270
Swedish Alzheimer Foundation
Grant: #FO2017-0243
Swedish Alzheimer Foundation
Grant: #ALZ2022-0006
Swedish government and the County Councils
Grant: #ALFGBG-715986
Swedish government and the County Councils
Grant: #ALFGBG-965240
European Union Joint Program for Neurodegenerative Disorders
Grant: JPND2019-466-236
National Institutes of Health
Grant: #1R01AG068398-01
National Institutes of Health
Grant: ZEN-21-848495
Alzheimer’s Association
Grant: #AARF-21-850325
BrightFocus Foundation
Grant: #A2020812F
Swedish Alzheimer Foundation
Grant: #AF-930627
Swedish Brain Foundation
Grant: #FO2020-0240
Agneta Prytz-Folkes & Gösta Folkes Foundation
Grant: #2020-00124
NIA NIH HHS
Grant: R01 AG068398
European Research Council
Grant: 101053962
Fluid Biomarkers for Neurodegenerative Dementias
European Research Council
Grant: 681712
Pathways to Alzheimer's disease
NIA NIH HHS
Grant: P30 AG062429
National Institutes of Health
Grant: 1R01AG068398-01
The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normal
European Commission
Grant: 860197
Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis
European Commission
Grant: 825664
ERA-NET to support the Joint Programming in Neurodegenerative Diseases strategic plan (JPND)
Swedish Research Council
Grant: unidentified
unidentified
Gamla Tjänarinnor Foundation
Erling-Persson Family Foundation
Gun and Bertil Stohnes Foundation
Marie Skłodowska-Curie
Wallenberg Scholar
International Society for Neurochemistry’s Career Development
Aina (Ann) Wallströms and Mary-Ann Sjöbloms Foundation
Anna Lisa and Brother Björnsson’s Foundation
Swedish Parkinson Foundation
Italian Ministry of Health, Ricerca Corrente
Olav Thon Foundation
Demensförbundet
Swedish Dementia Foundation
FWCI
21.89
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis
Additional file 1 of Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis
Additional file 4 of Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
Additional file 4 of Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
Additional file 3 of Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
Additional file 3 of Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
Additional file 1 of Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
Additional file 2 of Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
Additional file 1 of Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI
Additional file 2 of Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI